DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
67.78
+1.75 (2.65%)
Oct 8, 2025, 4:00 PM EDT - Market closed
DexCom Revenue
DexCom had revenue of $1.16B in the quarter ending June 30, 2025, with 15.21% growth. This brings the company's revenue in the last twelve months to $4.30B, up 9.30% year-over-year. In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth.
Revenue (ttm)
$4.30B
Revenue Growth
+9.30%
P/S Ratio
6.18
Revenue / Employee
$417,553
Employees
10,300
Market Cap
26.58B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
DXCM News
- 2 days ago - DexCom May Be The Most Underrated Growth Story In Healthcare - Seeking Alpha
- 6 days ago - Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time. - Business Wire
- 20 days ago - Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA - Benzinga
- 24 days ago - Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 2025 - Business Wire
- 4 weeks ago - DexCom, Inc. (DXCM) Presents At Baird Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Dexcom Launches Its First Open Call to Uncover the Next Diabetes Advocates Ahead of World Diabetes Day - Business Wire
- 5 weeks ago - DexCom, Inc. (DXCM) Presents At 2025 Wells Fargo Healthcare Conference (Transcript) - Seeking Alpha
- 5 weeks ago - DexCom, GE, SLB: Why Experts Rate These Stocks at Strong Buy - Kiplinger